CUREVO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://curevovaccine.com
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Phase 2
Active, not recruiting
- Conditions
- ShinglesHerpes Zoster
- Interventions
- Biological: CRV-101 Vaccine Antigen High DoseBiological: CRV-101 Vaccine Adjuvant Low DoseBiological: CRV-101 Vaccine Antigen Low DoseBiological: CRV-101 Vaccine Adjuvant Middle DoseBiological: CRV-101 Vaccine Adjuvant High Dose
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Curevo Inc
- Target Recruit Count
- 876
- Registration Number
- NCT05304351
- Locations
- 🇺🇸
Curevo Investigational Site, San Antonio, Texas, United States
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Herpes ZosterVaricella Zoster
- Interventions
- Biological: CRV 101Biological: Placebo
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Curevo Inc
- Target Recruit Count
- 90
- Registration Number
- NCT03820414
- Locations
- 🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath